GSK plc announced on December 12, 2025, that depemokimab received a positive opinion from the CHMP for treating severe asthma and chronic rhinosinusitis, potentially benefiting millions and requiring only two doses per year. The treatment showed a 54% reduction in severe asthma attacks.